NEW YORK (GenomeWeb) – Researchers at the University of Helsinki have demonstrated that circulating tumor DNA (ctDNA) can be used to find clinically actionable alterations in high-grade serous ovarian cancer (HGSOC) patients undergoing chemotherapy treatment, and that detecting these mutations can predict which patients will have better or worse outcomes.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.